Fig 1: Role of Rac GTPase activating protein 1 (RacGAP1) in promoting epithelial ovarian cancer (EOC) cell migration and invasion. A, RNAi efficiency of RacGAP1-siRNAs was tested by Western blotting, using scrambled siRNA (scram) as the negative control. B, Migration and (C) invasion capacities of OV-90 cells were upregulated upon RacGAP1-overexpression (o/e), whereas RacGAP1-siRNA inhibited cell malignancy. D,E, The same experiments were carried out on another serous EOC cell line, the Caov-3 cell line, and showed consistent results. All experimental data were from three independent experiments and analyzed by Student's t test. Bar, mean ± standard deviation. *P < .05
Fig 2: Kaplan-Meier curves for overall survival and progression-free survival according to Rac GTPase activating protein 1 (RacGAP1) expression and different clinicopathological features in epithelial ovarian cancer (EOC) patients. Patients with (A) higher RacGAP1 expression level, (B) positive lymph node metastasis, (C) advanced International Federation of Gynecology and Obstetrics (FIGO) stage and (D) higher serum CA-125 level exhibited unfavorable overall survival. E-H, Similarly, progression-free survival was also evaluated by plotting Kaplan-Meier curves. All statistical significance was compared by using log-rank test
Fig 3: Rac GTPase activating protein 1 (RacGAP1) positively regulate activation of RhoA and Erk proteins. A, Overexpression of RacGAP1 inhibited GTP-Rac1 expression, whereas it enhanced GTP-RhoA and p-Erk levels. Namely, knockdown of RacGAP1 by siRNA increased GTP-Rac1 level while it attenuated GTP-RhoA and p-Erk expression. B, Representative expression of RacGAP1 and p-Erk in clinical epithelial ovarian cancer (EOC) tissue samples, which showed significant statistical correlations as revealed by ?2-test (P = .003, [C])
Fig 4: Expression of Rac GTPase activating protein 1 (RacGAP1) in epithelial ovarian cancer (EOC) tissues and its correlations with clinicopathological parameters. A, Representative high expression of RacGAP1 in the nucleus of EOC cells. B, Representative low expression of RacGAP1 in EOC tissue samples. Proportion of high-RacGAP1 expression is higher in patients with (C) poor differentiation grade, (D) positive lymph node metastasis, (E) advanced International Federation of Gynecology and Obstetrics (FIGO) stage, and (F) positive tumor cells in ascetic fluid. Data were analyzed by ?2-test
Supplier Page from Abcam for Anti-RACGAP1/MGCRACGAP antibody